Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1;26(21):5638-5645.
doi: 10.1158/1078-0432.CCR-20-1899. Epub 2020 Aug 17.

Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy

Sebastian Klein #  1   2 , Alexander Quaas #  3 , Ka-Won Noh  3 , Maria Cartolano  4   5 , Nima Abedpour  4   5 , Cornelia Mauch  6 , Jennifer Quantius  3 , Hans Christian Reinhardt  7 , Reinhard Buettner  3 , Martin Peifer  8   5 , Doris Helbig  9
Affiliations

Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy

Sebastian Klein et al. Clin Cancer Res. .

Abstract

Purpose: Pleomorphic dermal sarcoma (PDS) is a rare malignant cutaneous tumor with an unknown cell of origin. Locally defined tumors can be treated by curative excisions, whereas advanced stages of the disease are difficult to treat, using standard regimens.

Experimental design: We performed whole-exome sequencing on a cohort of 28 individuals and corresponding transcriptomic analysis on 21 patients, as well as quantitative IHC image analysis on 27 patients.

Results: PDS exhibits a universally high mutational load (42.7 mutations/mega base) with an inflamed, immunogenic tumor microenvironment. Three cases of PDS showed response to immune checkpoint blockade. Local mutation rate variation together with mRNA expression data demonstrate that PDS form a distinct entity, with PDGFRB as a lineage marker. In addition, we found that PDS is of mesenchymal, fibroblastic differentiation.

Conclusions: PDS is of fibroblastic differentiation and exhibits a strong susceptibility to immunotherapy, including a high mutational burden and an inflamed tumor microenvironment.

PubMed Disclaimer

References

    1. Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012;36:1317–26.
    1. Persa OD, Loquai C, Wobser M, Baltaci M, Dengler S, Kreuter A, et al. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. J Eur Acad Dermatol Venereol. 2019;33:1577–80.
    1. Tardio JC, Pinedo F, Aramburu JA, Suarez-Massa D, Pampin A, Requena L, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol. 2016;43:101–12.
    1. Mentzel T, Requena L, Brenn T. Atypical fibroxanthoma revisited. Surg Pathol Clin. 2017;10:319–35.
    1. Lai K, Harwood CA, Purdie KJ, Proby CM, Leigh IM, Ravi N, et al. Genomic analysis of atypical fibroxanthoma. PLoS One. 2017;12:e0188272.

Publication types

MeSH terms

LinkOut - more resources